199 related articles for article (PubMed ID: 24628993)
1. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of RON in small and non-small cell lung cancers.
Kanteti R; Krishnaswamy S; Catenacci D; Tan YH; EL-Hashani E; Cervantes G; Husain AN; Tretiakova M; Vokes EE; Huet H; Salgia R
Genes Chromosomes Cancer; 2012 Sep; 51(9):841-51. PubMed ID: 22585712
[TBL] [Abstract][Full Text] [Related]
3. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Kanteti R; Nallasura V; Loganathan S; Tretiakova M; Kroll T; Krishnaswamy S; Faoro L; Cagle P; Husain AN; Vokes EE; Lang D; Salgia R
Lab Invest; 2009 Mar; 89(3):301-14. PubMed ID: 19139719
[TBL] [Abstract][Full Text] [Related]
4. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
5. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
6. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
[TBL] [Abstract][Full Text] [Related]
7. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
8. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
[TBL] [Abstract][Full Text] [Related]
9. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
[TBL] [Abstract][Full Text] [Related]
11. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.
Hao C; Cui Y; Chang S; Huang J; Birkin E; Hu M; Zhi X; Li W; Zhang L; Cheng S; Jiang WG
Sci Rep; 2019 Dec; 9(1):18101. PubMed ID: 31792339
[TBL] [Abstract][Full Text] [Related]
12. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
Shi W; Song J; Wang W; Zhang Y; Zheng S
Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
[TBL] [Abstract][Full Text] [Related]
13. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.
Kabbout M; Garcia MM; Fujimoto J; Liu DD; Woods D; Chow CW; Mendoza G; Momin AA; James BP; Solis L; Behrens C; Lee JJ; Wistuba II; Kadara H
Clin Cancer Res; 2013 Jul; 19(13):3383-95. PubMed ID: 23659968
[TBL] [Abstract][Full Text] [Related]
14. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.
Tsao MS; Liu N; Chen JR; Pappas J; Ho J; To C; Viallet J; Park M; Zhu H
Lung Cancer; 1998 Apr; 20(1):1-16. PubMed ID: 9699182
[TBL] [Abstract][Full Text] [Related]
17. Expression of the recepteur d'originenantais receptor tyrosine kinase in non-small cell lung cancer and its clinical significance.
Han WL; Li WD; Hu J; Rusidanmu A; Chen LF; Shen L; Zheng SS
Chin Med J (Engl); 2012 Mar; 125(6):1110-4. PubMed ID: 22613539
[TBL] [Abstract][Full Text] [Related]
18. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
[TBL] [Abstract][Full Text] [Related]
19. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
20. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.
Gumustekin M; Kargi A; Bulut G; Gozukizil A; Ulukus C; Oztop I; Atabey N
Pathol Oncol Res; 2012 Apr; 18(2):209-18. PubMed ID: 21779788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]